Nalbuphine hydrochloride extended release PK in hemodialysis patients and pruritus

6^th Annual conference on Clinical & Pediatric Nephrology

May 09-10, 2016 New Orleans, USA

Harry W Alcorn

DaVita Clinical Research, USA

Posters & Accepted Abstracts: J Nephrol Ther

Abstract :

Uremic pruritus is a common and deleterious condition among hemodialysis (HD) patients and is known to affect about up to 50% of patients with renal failure and often causes long term pain and suffering. It is a distressing problem for the patients and is independent of gender, age, ethnicity, types of dialysis and the etiology of the underlying renal disease; among the factors causing pruritus in ESRD, the accumulation of uremic toxins, systemic inflammation, cutaneous xerosis and common comorbidities e.g., diabetes mellitus and viral hepatitis. Currently, there are no approved treatments in the United States or Europe. Uremic pruritus is typically treated with creams, antihistamines, ultraviolet radiation and the off-label use of various drugs, including opioids with limited success. To date, uremic pruritus remains an unresolved problem with renal transplantation being the only effective treatment. Nalbuphine HCL ER is a mixed �¼-antagonist and �º-agonist opioid drug was evaluated in hemodialysis patients. Central gating of �¼/�º opiate circuitry plays an important role in mediating and countering pruritogenic sensation. However, as a class, kappa opioid agonists have aquaretic effects in both animals and humans, which can be treatment limiting. Nalbuphine HCl ER tablets can be safely administered to HD patients without dose adjustment up to 240 mg BID and may hold promise in treating uremic pruritus.

Biography :

Email: Harry.Alcorn@davita.com